

## Special Issue

# Epigenetic Regulators and Cancer Precision Therapies

### Message from the Guest Editor

Tumorigenesis originated from two gene alterations: a tumor suppressor gene and a proto-oncogene/oncogene. When this gene mutates, a tumor suppressor gene causes a loss or reduction in its protection. Epigenetics and epigenomics can improve our understanding of cancer development and progression, explain the regulation of gene expression, and address genomic function without the base-pair DNA sequence. This Special Issue, titled “**Epigenetic Regulators and Cancer Precision Therapies**”, presents a collection of contributions by outstanding researchers that focus on the fields of cancer epigenetics and epigenomics for precision treatment. This collection of articles provides a snapshot of the latest research, encompassing diverse aspects of epigenetic regulation in cancer. We anticipate further breakthroughs that will transform the landscape of cancer treatment and improve patient outcomes.

---

### Guest Editor

Dr. Biaoru Li  
Department of Pediatrics, GA Cancer Center, Augusta, GA 30913, USA

---

### Deadline for manuscript submissions

closed (31 October 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/219933](https://mdpi.com/si/219933)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)